Clinical Trials

The James Cancer Center Columbus, OH

open for enrollment

Ph II Stdy of Neratinib w/ or w/o Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer

Protocol: OSU-17351

Full Title

A Phase II Study of Neratinib with or without Fulvestrant in HER2-Positive, ER-Positive Metastatic Breast Cancer

Breast Cancer